UK drug-cost watchdog backs Sovaldi, Achillion touts HCV interim results, Avastin's latest cancer indication, Ebola outbreak worsens, COPD drug gets panel nod, and study links quick reviews and black-box warnings.
These healthcare plans allow employees and employers to avoid ACA penalties but provide little coverage.
Layoffs are reported to be in the offing.
The Scottish Medicines Consortium gave a thumb's down to GSK's drug and a Boehringer COPD drug.
Britain's National Institute for Health and Care Excellence has followed through on its Kadcyla objections and has said Roche's breast cancer drug will remain off the National Health Services formulary because it is too expensive.
Medibid users auction up care in exchange for a low price.
The PBM dropped 25 more drugs from its formulary.
Innovation is still valued in the orphan-drug space, but the reimbursement bar is rising. NPS Pharma's Eric Pauwels, who's launched five ultra-rare disease products, explains how these biotech brands can demonstrate their value. Marc Iskowitz reports
Disclosed in its earnings report yesterday, Gilead may have a card up its sleeve to counter Merck's experimental hep. C combo regimen.
In the latest chapter in the Sovaldi pricing saga, Senators Ron Wyden and Charles Grassley urge Gilead to clarify Sovaldi sticker shock.
UnitedHealthcare finds drug costs more than doubled.
French lawmakers have the chance to vote for off-label use of Avastin, potentially eating into the turf of higher-priced Lucentis.
Health insurers and pharmacies signed a letter asking the FDA to require biosimilars and branded biologics to share the same name.
Celebrity endorsement, co-pay cards and online edutainment are some of the ways marketers are dueling for attention in the prescription omega-3 space.
The Centers for Medicare and Medicaid Services launched a new site Monday to help patients understand how to use their health coverage.
The Italian Medicines Agency is guiding patients away from Roche's costlier AMD-indicated Lucentis.
The Oregon Health Plan wants to keep hep. C medications Sovaldi and Olysio off its list of covered treatments.
Patients will now be able to submit specialty prescriptions at the national chain's retail stores.
Companies including WellPoint and Highmark are deploying financial incentives for doctors to stick with recommended cancer treatments.
With pollen season approaching its peak, drugmakers are educating doctors on a new class of allergy tablets. It could be a while before they're made available for patients.
The AIDS Healthcare Foundation took out an ad in some WSJ editions saying the drug threatens to "break the bank."
The drugmaker sent Olysio + Sovaldi to regulators for an additional indication in HCV patients with liver scarring.
An EY report finds that pharma is not only failing to give payers the right type of drug data, but that industry has a lot of trust-building to do before they will accept it.
An analysis by Bloomberg today shows why drug pricing "keeps defying the law of gravity."
Express Scripts said treatments for diabetes are the most expensive of the traditional medications, while specialty drugs are eating up a significant portion of total drug spend.
Merck has broadened its analytics approach to include team-ups with a slate of organizations at the intersection of Big Data and health IT.
Around 25% of 18-34 year-olds have signed up for coverage. Obama's FunnyorDie appearance drives HHS traffic.
As the Affordable Care Act rolls out, the behaviorists at MicroMass surveyed stakeholders about the impact on industry. Jessica Brueggeman sorts out the diverse views and asks: Can healthcare reform lead pharma to operationalize its patient focus?
A study shows consumers are increasingly pleased with retail pharmacies, compared to mail order pharmacies, which are often considered a key means of driving adherence and lowering healthcare coverage costs.
Researchers says growth will average 5.8% a year between 2012 and 2022. They also anticipate generics will hit a leveling-off point that will drive average Rx prices upwards
Researchers say using additional data points offers greater insight into patient-adherence patterns.
Benefits research studies show employers expect to lay out 7% more in healthcare costs in 2014, a move that has not been accompanied by lower employee costs.
The drugstore chain says it has cut off over-prescribers of tightly controlled medications.
Data show doctors are increasingly leaning on Regeneron's Eylea over Roche's Lucentis, as the two battle for share of the wet-AMD market.
While payers' proclivity for print is well-known, many prefer to receive pharma resources digitally, research shows. Joe Dysart on tools that work for this segment.